Mitochondrial genome and its regulator TFAM modulates head and neck tumourigenesis through intracellular metabolic reprogramming and activation of oncogenic effectors

Yi-Ta Hsieh, Hsi-Feng Tu, Muh-Hwa Yang, Yi-Fen Chen, Xiang-Yun Lan, Chien-Ling Huang, Hsin-Ming Chen and Wan-Chun Li

© The Author(s) 2021

Mitochondrial transcriptional factor A (TFAM) acts as a key regulatory to control mitochondrial DNA (mtDNA); the impact of TFAM and mtDNA in modulating carcinogenesis is controversial. Current study aims to define TFAM mediated regulations in head and neck cancer (HNC). Multifaceted analyses in HNC cells genetically manipulated for TFAM were performed. Clinical associations of TFAM and mtDNA encoded Electron Transport Chain (ETC) genes in regulating HNC tumourigenesis were also examined in HNC specimens. At cellular level, TFAM silencing led to an enhanced cell growth, motility and chemoresistance whereas enforced TFAM expression significantly reversed these phenotypic changes. These TFAM mediated cellular changes resulted from (1) metabolic reprogramming by directing metabolism towards aerobic glycolysis, based on the detection of less respiratory capacity in accompany with greater lactate production; and/or (2) enhanced ERK1/2-Akt-mTORC-S6 signalling activity in response to TFAM induced mtDNA perturbance. Clinical impacts of TFAM and mtDNA were further defined in carcinogen-induced mouse tongue cancer and clinical human HNC tissues; as the results showed that TFAM and mtDNA expression were significantly dropped in tumour compared with their normal counterparts and negatively correlated with disease progression. Collectively, our data uncovered a tumour-suppressing role of TFAM and mtDNA in determining HNC oncogenicity and potentially paved the way for development of TFAM/mtDNA based scheme for HNC diagnosis.

Cell Death and Disease (2021) 12:961; https://doi.org/10.1038/s41419-021-04255-w

INTRODUCTION

The progression of malignant transformation from non-neoplastic cells to tumourous cells can be achieved only by contribution of a series of cellular events [1]. In the aspect of energy production, it is widely accepted that, when compared to normal cells, cancer cells are more prone to consume greater glucose thereby forming lactate by a glycolytic pathway regardless of oxygen availability [2]. Indeed, a number of studies have shown that enzymes involved in central carbon metabolism including glycolysis and Pentose Phosphate Pathway (PPP) as well as de novo lipogenesis and glutaminolysis are enhanced in tumours compared with their normal counterparts; the mitochondrial related metabolic activity, on the other hand, is often downregulated [3–6].

To date, most investigations focus on the role of glycolytic enzymes in regulating tumourigenesis [7, 8], mainly due to the fact that a molecular basis differential expression of glycolytic enzymes and glucose transporters has been shown to correlate with mutations of a classic tumour suppressor protein TP53 in most cancers [9]. The roles of mitochondrial cues in controlling cellular malignancy, however, have been under appreciated. For example, mitochondrial aldehyde dehydrogenase (ALDH) could facilitate cytosolic NADH content which serves as an electron donor to trigger ATP production, thereby promoting tumour progression [10]. A high level of glutamine transporter (SLC1A5) and glutaminases (GLS), two key factors involved in the conversion of glutamine into glutamate supplying nitrogen for anaplerotic flux to TriCarboxylic Acid (TCA) cycle, was detected in c-myc driven cancers [11]. Interestingly, enhanced Electron Transport Chain (ETC) activity was found in Venetoclax-resistant multiple myeloma cells while application of ETC inhibitor IACS-010759 and thienoyltrifluoroacetone (TFFA) could sensitize resistance to Venetoclax through the ATF4-BIM-NOXA pathway [12] indicating that mitochondrial activity may not necessarily be downregulated during tumourigenesis. In addition to metabolic enzymes or transporters, accumulating "oncometabolites" due to defective TCA cycle enzymes, such as fumarate hydratase (FH),

1Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan. 2Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan. 3Division of Medical Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. 4Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. 5Office of Health Technology and Informatics (HTI), The Hong Kong Polytechnic University (PolyU), Hung Hom, Kowloon, Hong Kong, SAR, China. 6School of Dentistry and Department of Dentistry, National Taiwan University Medical College and National Taiwan University Hospital, Taipei, Taiwan. 7email: wcli@nycu.edu.tw

Received: 4 May 2021 Revised: 25 September 2021 Accepted: 4 October 2021

Published online: 18 October 2021

Official journal of CDDpress
sucinate dehydrogenase (SDH) and isocitrate dehydrogenase (IDH), were also detected in tumour cells implying that deregulated mitochondrial metabolites might also underlie oncogenic transformation [13, 14].

Mitochondria are a double-membrane organelle that contributes to energy production in most eukaryotic organisms via various bioenergetic processes including the TCA cycle, ETc and lipid catabolism. A variety of cellular processes such as cell apoptosis, differentiation, calcium homeostasis and hormone biosynthesis occur in different mitochondrial compartments [15, 16]. With distinct structural and physiological functions, mitochondria are interestingly regarded as an independent "organism" in a cell based on the fact that mitochondria have their own genome, named mitochondrial DNA (mtDNA) [17], and that mitochondria could be horizontally transferred between cells resulting in different pathophysiological consequences [18]. In humans, mtDNA is a circular genomic material and encodes 13 ETC protein subunits [17]. At the molecular level, mitochondrial transcription factor A (TFAM) plays a key role in controlling mtDNA packing, replication, and transcription [17]. In brief, most studies suggest that impaired mitochondrial genome and mtDNA regulator TFAM in controlling HNC malignancy.

In clinical studies, lower mtDNA and TFAM is associated with poorer survival in ovarian cancer [19], oesophageal squamous cell carcinoma [20], colorectal cancer [21] as well as oral squamous cell carcinoma [22]. At cellular basis, decreased TFAM and mtDNA content led to lower mitochondrial activity resulting in greater lactate production, increased cell proliferation and enhanced metastatic capacity in breast cancer [23], intestinal cancer [24], oesophageal cancer [20], and cisplatin (CDDP) resistant ovarian cancer [19]. A more recent study showed that TFAM mediated regulations for oncogenicity in various cancers probably occur via the disruption of LC3-II-mediated autophagy [25]. Until now, an impact of TFAM/mtDNA in modulating cellular, molecular and metabolic identity of Head and Neck Cancer (HNC) remains elusive. Our recent study demonstrated that manipulation of a rate-limiting factor of Pyruvate Dehydrogenase complex (PDC), and Pyruvate Dehydrogenase E1 subunit (PDHA1) that controls the metabolic fate of lactate entering into mitochondria, could sufficiently enhance HNC cellular malignancy [26]. This is interesting to further verify the role of mitochondrial genome and mtDNA regulator TFAM in controlling HNC malignancy.

### MATERIAL AND METHODS

**Chemical, cell culture, animal and clinical tissues**

Puromycin, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), CDDP, 5-flouracil (5-FU), and Extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor PD98059 were purchased from Sigma-Aldrich. Protein kinase B (PKB/Akt) inhibitor MK-2206 was obtained from Selleckchem. The source and culture conditions of HNC cells (all are Human Papilloma Virus negative (HPV−)) from different origins as well as HNC bearing xenograft tumour growth assay [under the approval of Institutional Animal Care and Use Committee (IACUC), National Yang Ming Chiao Tung University (NYCU)] were described elsewhere [26, 27]. In brief, the same kind of 10^6 control (shLuc) and TFAM deficient HNC cells were transplanted in opposite side of flank in the same male nude mouse (5–7 weeks, NOD-SCID, Crl:NIH from Charles River). The tumour size was followed every week and at the 4th week post transplantation, tumours were excised and weighted. The power density was 87 mW/cm^2 and the period of light treatment was set at 11.49 s to deliver an energy dose of 1 joule/cm^2 [28]. Establishment of chemotherapeutic and PhotoDynamic Therapy (PDT) resistance HNC cells

**In vitro cell growth analysis**

Cell growth was measured by both MTT assay and Trypan blue exclusion assay while the cell cycle, Annexin V-FITC based cell apoptosis, transwell-based cell migration, drug resistance assay, quantitative real-time PCr (qRT-PCR), and Western blot analysis was previously described [26]. Primers for qRT-PCR analysis (Table S3) and antibodies used for Western blot and Immunocytometry (ICC) analysis are listed (Table S4). For ICC analysis, cells were seeded on 20 x 20 mm cover slides and cultured in indicated medium. Staining protocols were followed with fixative and compatible with the secondary antibodies. The images were captured using a fluorescence microscope (Olympus AX70) fitted with a digital camera (Olympus DP70) and were quantified using Image J software.

**Establishment of TFAM deficient and overexpressing HNC cells**

Plasmids encoding small hairpin RNAs (shRNA) targeting 3′-untranslated regions (3′-UTR) of TFAM gene (shTFAM) were obtained from the National RNAi Core Facility, Academia Sinica, Taiwan (Table S2). The lentiviral vectors encoding shTFAM and the control shRNA targeting Luciferase (shLuc) were produced in 293 T cells for infection into HNC cells by using gene juice transfection reagent. HSC3 cells encoding clone A shTFAM, OECM1 cells encoding clone B shTFAM and SAS/FaDu cells encoding clone C shTFAM were selected for further experiments based on their knock-down efficiency. Stable knockdown cell lines were maintained in indicated complete medium containing 2.5 μg/ml puromycin. For making the TFAM overexpressing vector, primers targeting wild-type TFAM gene carrying BamHI(5′-CGAGGATCCACATTGGCGGCCTTCCTCCGAAGC-3′) and NotI (5′-GATCGGCCGCTACACTCTCTGAGACCTATA-3′) restriction enzyme sequences were used to amplify full length TFAM cDNA from SAS cells, which encode wild-type TFAM, using the Platinum PCR SuperMix High Fidelity system (Invitrogen™). The PCR products were then cloned into the pcDNA4/myc-His-A,B,C vector (Thermo Fisher Scientific) between BamHI and NotI. Candidate colonies were selected, amplified (Plasmid Midi kit, Geneaid) and sequence was verified before transfection. For TFAM overexpression in HNC cells, TransFect™ Lipid Reagent (BIO-RAD) was utilized following the manufacturer’s instructions.

**Determination of half maximal inhibitory concentration (IC50) of chemotherapeutic agents**

The assay to define IC50 of different chemotherapeutic agents in HNC cells was performed by analysing cell viability of cells treated with serial diluted chemotherapeutic agents. While the inhibitory rates, defined as the percentage of mean OD value in treatment group to the mean OD value in control group plotted versus chemotherapeutic agents concentrations, IC50 could be calculated in Prism 5 using non-linear regression analysis followed by the panel of equations “Dose-response curves—Inhibition” and an equation (log inhibitor concentration) vs. normalized response.

**Establishment of chemotherapy and PhotoDynamic Therapy (PDT) resistance HNC cells**

The CDDP resistant, 5FU resistant and PDT resistant HNC cells were generated by applying increasing dose of candidate drugs/treatment for multiple selection cycles onto parental HNC cells (sensitive counterpart). In brief, HNC cells were treated with low-dose CDDP and 5FU for 48 h, allowed the cells to recovery up to 70–80% confluency, passaged for two times in the fresh medium without drugs and applied higher dose of drugs for further selection. CDDP and 5FU resistant HNC cells could be obtained after repeating procedure for five times. For establishment of PDT resistant HNC cells, parental cells were pre-treated with 1 mM 5-aminolevulinic acid (ALA) for 3 h followed the irradiation of red light (wave length: 635 ± 5 nm) at different dose in Ca9-22 and SAS cells and 48-h recovery before the next round of treatment. PDT resistant HNC cells could be obtained after repeating procedure for 5 times. The power density was 87 mW/cm^2 and the period of light treatment was set at 11.49 s to deliver an energy dose of 1 joule/cm^2 [28]. Establishment of chemotherapeutic and PhotoDynamic Therapy (PDT) resistance HNC cells

**Fluorogenic Caspase-3 activity assay**

Cells were seeded in 96-well plate for 24 h, rinse cell with ice-cold PBS and spin the plate at 300g for 10 min. Cell lysates were collected by cell lysis buffer on ice for further use. Caspase-3 activity was detected following the manufacturer’s instructions (Cell signalling, Kit#5723). N-Acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) is used as the fluorogenic substrate while activated Caspase-3 cleaves this substrate between
DEVD and AMC, generating highly fluorescent AMC that is detected using TECAN SPARK multimode microplate readers at IRC, NYCU. Fluorescence intensity was measured with excitation wavelength at 380 nm and emission wavelength at 450 nm at 37 °C.

**Metabolic assays**

Lactate colorimetric/fluorometric assay kit, ATP colorimetric/fluorometric Assay kit, Pyruvate assay kit, PDH Activity Colorimetric Assay kit (Biovision) and Glucose Uptake Cell-based Assay kit (Cayman Chemical) were performed following the manufacturer's instructions. Colorimetric measurements for optical density (OD) and flow cytometrical analysis were performed using TECAN SPARK multimode microplate readers and Beckman Coulter CytoFLEX, respectively, at IRC, NYCU.

**Mitochondrial assays**

To determine Oxygen Consumption Rates (OCRs), Seahorse XF bioanalyzer was used following the manufacturer's instructions. The relative mtDNA copy number was measured by qRT-PCR. MitoTracker™ Red CMXRos, Carboxy-DCFDA, MitoSOX™ Red and Tetramethylrhodamine, ethyl ester (Thermo Fisher Scientific) were used to detect mitochondrial mass and activity, respectively, using flow cytometrical analysis by Beckman Coulter CytoFLEX. Living cells were also stained with MitoTracker™ Red CMXRos, followed by fixation of 4% PFA and counterstained for nuclei by DAPI. Images were captured using Zeiss LSM880 with AiniScan at IRC, NYCU. Final images were processed using Adobe Photoshop or Photomerge X3.

**Metabolomics analysis**

Cellular metabolites were analysed using Liquid Chromatography-Mass Spectrophotometry (LC-MS) at Metabolomics Core laboratory at NYCU. In brief, 10^5 cells were washed with PBS and treated with LC-MS grade iced methanol and water followed by vigorous vortexing and centrifugation to remove cell debris. The supernatants were collected for LC-MS metabolic profiling analysis.

**RNA sequencing analysis for chemical-induced mouse tongue cancer**

For time-course tongue cancer induction, previously used carcinoigen 4-nitroquinoline-1-oxide (Nqo, Sigma-Aldrich) was freshly prepared in 1,2-propylene glycol (Sigma-Aldrich) and fed in water (final concentration, 100 μg/ml) for 6–8 weeks old C57BL/6 mice based on protocol described previously [29]. At the indicated time point (8-, 12- and 16-weeks post-treatment), the mice were sacrificed and tongue tissues were harvested and preserved in RNAlater for RNA sequencing (RNA-seq) analysis. For RNA-seq analysis, total RNAs were subjected to cDNA synthesis and NGS library construction using the Universal Plus mRNA-Seq (NuGEN Technologies, Redwood City, CA, USA). The quality and average length of sequence library for each sample was assessed using Bioanalyser (Agilent Technologies, Santa Clara, CA, USA) and the DNA 1000 kit, respectively. The indexed samples were pooled equimolarily and sequenced on Illumina NovaSeq 6000 (150 base, paired-end reads) (Illumina, San Diego, CA, USA). The quantification of raw reads was processed using CLC Genomics Workbench v.10 software. Adaptor sequences and base with low quality or ambiguously were trimmed. The quality screened reads were mapped to Mus musculus GRCm38 genome using CLC Genomics Workbench. The mapping parameters were the following: mismatch cost 2, insertion cost 3, deletion cost 3, length fraction of 0.5 and similarity fraction of 0.8. The expression values were calculated as FPKM (Fragments Per Kilobases per Million). The differential gene expression between two or more condition was based on the fold changes of FPKM value. The genes with 2-fold change were further analysed.

**Statistical analysis**

All experiments were performed from more than three independent biological preparations and each experimental value was marked as a dot in bar graphs. For real-time RT-PCR assay (Fig. 2H, I & J), the statistical analysis was performed to compare the 2^(-ΔΔCt) values of control and experimental groups from three biological replicates. All analyses were performed using the statistical software program package Prism 5. The differences in the clinical characteristics between two groups were analysed by Chi-square test and student's t-tests. Differences were assumed to be significant when the p value was <0.05.

**RESULTS**

**Changing TFAM/mitDNA modulates HNC malignancy**

To examine the roles of TFAM and its targeting mtDNA during HNC development, multiple in vitro analyses in HNC cells, with different origins in response to TFAM changes, were performed. The results showed that TFAM mRNA and protein expression is reduced in most HNC cells in contrast to normal human oral fibroblasts (OF) (Fig. 1A and Fig S1A). Next, HNC cells deficient (Fig. 1B) or enforced expressing for TFAM (Fig S1B) were utilized to better determine the role of TFAM in controlling HNC tumourigenicity. In addition to protein expression, decreased expression of mtDNA encoded ETC subunits (TFAM targets) including ND1, ND2, ND3, ND4, ND4L, ND5, NDS, Complex I, Cyb (Complex III), Cox I, Cox II, Cox III (Complex IV) as well as ATP8, ATP6 (Complex V) were detected by real-time and Western blot PCR analysis in TFAM-silenced HNC cells when compared with control cells (Fig. 1C, D). In agreement with this finding, enforced expression of TFAM also positively correlated with expression of mtDNA encoded HTC genes in TFAM overexpressing HNC cells (Fig. S1C). While no significant changes for nuclear encoded ETC proteins (NDUFB8, SDHB, UQCRCC2, ATP5A) were found in TFAM knockdown HNC cells, mtDNA encoded COXII protein was greatly down-regulated in TFAM-silenced SAS, OECM1 and HSC3 cells (Fig. S1D), highlighting the knockdown efficiency and specificity in our experimental setting. In short, shRNA mediated TFAM silencing could functionally reduce TFAM and its targeting cues in HNC cells.

Next, multifaceted cellular assays were performed in TFAM knockdown and overexpressing HNC cells. By using Trypan blue exclusion assay, it was shown that TFAM knockdown led to increased HNC cell proliferation in vitro, whereas overexpression of full-length wild-type human TFAM (hTFAM) effectively down-regulated cell growth in TFAM-silenced HNC cells (Fig. 2A). Similar to in vitro growth, significant larger TFAM-silenced OECM1- and HSC3-, but not SAS- and FaDu-, bearing xenograft tumours were detected in vivo (Fig. 2B and Fig. S2), implying that TFAM expression is negatively associated with HNC cell growth. This result showing differential growth behaviours between tested TFAM-silenced HNC cells could possibly attribute to distinct differences in single nucleotide variation (SNV), copy number, mRNA abundance, methylation, and tumor microenvironment (TME) profiles in different HPV HNC cells, as reported by a very recent study [30]. At mechanistic basis, further analysis found that TFAM silencing slightly altered cell cycle phase distribution as enforced hTFAM expression significantly arrested HNC cell cycling (Fig. 2C). Moreover, by using Annexin V based apoptosis analysis and Caspase-3 activity assay, decreased apoptotic rate and reduced Caspase-3 activity was detected in TFAM-silenced HNC cells while hTFAM re-introduction predominantly triggered cellular apoptosis in both control and TFAM-silenced HNC cells (Fig. 2D, E). In sum, cell cycling and cell apoptosis both underlie TFAM mediated regulation for HNC cell growth.

As enhanced metastatic activity and drug resistance are also hallmarks of cancer cells [31, 32], cell motility and chemotherapeutic sensitivity was next assessed in HNC cells differentially expressed TFAM. By using transwell-based migration assays, TFAM loss significantly promoted HNC cell migration compared with control cells, as hTFAM overexpression largely attenuated this effect (Fig. 2F). As for the changes of therapeutic sensitivity in response to reduced TFAM expression in HNC cells, the half maximal inhibitory concentrations (IC50) for CDDP and 5FU, the most common chemotherapeutic agents for HNC in clinic, were determined. A greater IC50 for CDDP and 5FU was detected in TFAM deficient HNC cells when compared with control cells (Fig. S3); strikingly, hTFAM overexpression significantly elevated CDDP and 5FU anti-HNC efficacy in TFAM-silenced HNCs (Fig. 2G). The findings are consistent with previous studies showing that alteration of mtDNA altered chemoresistance in pancreatic
cancers, suggesting that lower mtDNA may contribute resistant ability to anti-cancer drugs [33, 34]. To further elaborate the impact of mtDNA content in controlling drug resistance in HNCs, the HNC cells resistant to CDDP and 5FU as well as adjuvant photodynamic therapy (PDT) were established and mtDNA encoded ETC gene expression was analysed in these treatment-resistant HNC cells (Fig. S4, Fig. S5A, B). The results showed that, in contrast to their sensitive counterparts, most mtDNA encoded ETC gene expressions were downregulated in resistant HNC cells (Fig. 2H, I, J and Fig. S5C). These findings uncovered that mtDNA loss positively associated with chemotherapy and PDT resistance, although the underlying regulation(s) between mtDNA dysfunction and treatment resistance remain unclear. Collectively, TFAM expression negatively correlated with cell malignancy in HNCs, confirming that TFAM acts as a tumour-suppressing factor in HNCs.

TFAM deficiency-induced Warburg phenotype in HNC cells
In addition to changes of intracellular signals, the metabolic plasticity was recently appreciated in numerous studies showing that cancers could evolve to adapt environmental stresses during progression [35]. Our previous findings demonstrated that manipulations for pyruvate metabolic molecules LDHA and PDHA1 led to a metabolic shift among a wide spectrum of metabolic pathways and further analysis confirmed that this metabolic reprogramming is essential for LDAH/PDHA1 mediated malignant changes in HNC cells [26]. We herein tested whether a metabolic shift could also be responsible for TFAM mediated cellular changes. Multiple bioenergetic readouts including glucose uptake, intracellular pyruvate level, extracellular lactate production, PDH activity and intracellular ATP level in TFAM silenced HNC cells were examined. No significant difference for glucose uptake activity and intracellular pyruvate content between TFAM silenced and control HNC cells was detected (Fig. 3A, B) whereas increasing ATP level is detected in TFAM silenced SAS, OECM1 and HSC3 cells (Fig. 3C). Interestingly, lactate secretion was elevated (Fig. 3D) while decreased PDH activity was detected using colorimetric assay (Fig. 3E), revealing an active metabolic reprogramming in HNC cells in response to TFAM loss. Interestingly, re-introduction of hTFAM into control and TFAM silenced HNC cells notably reverted these metabolic alterations, signifying the TFAM mediated metabolic regulations in HNC cells.

TFAM mediated metabolic shift was further evident by a LC-MS based metabolomics analysis for glycolytic and TCA cycle metabolites. The analyses shows that only metabolites in the “payoff” phase of glycolysis including 1,3 bisphosphoglyceraldehyde, 2-/3-phosphoglycerate, and phosphoenolpyruvate (PEP) were decreased in TFAM silenced SAS and HSC3 cells (Fig. 3C). This result could be explained as a consequence of higher glycolytic metabolism in response to TFAM loss, thereby leading to a greater consumption of glyceraldehyde-3-phosphate (G-3-P) in order to meet energetic demand. As new glucose input was not significantly altered, we further suspected that there might be alternative changes of other cellular metabolic cues, such as amino acid metabolism, that could potentially compensate deregulated mitochondrial activity in a condition of TFAM knockdown to support tumorigenic activity in HNC cells. Nevertheless, no significant changes for amino acid level were found in TFAM silenced HNC cells when compared with control.

Fig. 1 TFAM alterations lead to functional mtDNA change in HNC cells. A Real-time RT-PCR analysis showed decreased TFAM mRNA expression in HNC cells compared with OFs. B Western blot analysis showed effective changes of TFAM expression in shRNA-mediated TFAM silencing. The clone C shTFAM infected SAS/FaDu cells, clone B shTFAM infected OECM1 cells and clone A shTFAM infected HSC3 cells are used for the experiments. Functional knockdown is evident using (C) real-time RT-PCR and (D) Western blot analysis showing significant downregulation of mtDNA-encoded ETC subunit genes in TFAM silencing HNC cells. Different ETC complex genes including Complex I (ND1, ND2, ND3, ND4, ND4L, ND5, ND6), Complex III (Cytb), Complex IV (E, Cox I, Cox II, Cox III) and Complex V (ATP8, ATP6) are indicated. Quantification of real-time RT-PCR analysis is represented as the fold changes of ETC gene expression in TFAM silencing (shTFAM) over control (shLuc) HNC cells. Quantification of Western blot analysis is represented as the fold changes of TFAM protein expression in TFAM silencing (shTFAM) over control (shLuc) HNC cells using Image J. Data are presented as Mean ± SEM (N = 3 independent biological replicates). *p < 0.05, **p < 0.01, ***p < 0.001.
The single-cell level, IFA further confirmed that TFAM overexpression (hTFAM) ameliorated this HNC cell overgrowth using Trypan exclusion assay. In vivo analysis for HNC-bearing xenograft tumour growth showed that TFAM loss resulted in significantly greater tumour mass compared with control tumours derived from OE CM1 and HSC3 groups, but not in tumours from SAS and FaDu cells. The size at each time point in TFAM-silenced and in control HNC bearing tumours were statistically analysed. Numbers of tumour grafts were indicated in parentheses. C Flow cytometry based cell cycle analysis showed that TFAM loss resulted in faster cell cycling, as lower cell population in G0/G1 phase and more cells are distributed in S and G2M phases were detected in TFAM-silenced HNC cells. In contrast, hTFAM overexpression suppressed cell cycling in HNC cells, both in control and TFAM-silenced groups. By using (D) Annexin V based flow cytometrical analysis and (E) Caspase-3 activity assay, TFAM loss resulted in lower apoptotic percentage an Caspase-3 activity in HNC cells whereas enforced hTFAM expression significantly upregulated apoptotic rates and Caspase-3 activity, both in control and TFAM-silenced HNC cells. F Cell migration was examined using transwell assay and quantification showed that TFAM loss promoted significant increase of HNC cell migration while hTFAM expression abolished this effect, both in shLuc and TFAM-silenced HNC cells. G Overexpression of hTFAM sensitized TFAM-silenced HNC cells to chemotherapeutic agents CDDP and SFU. Cell viability of TFAM-silenced HNC cells transfected with VA or hTFAM in response to 10 μM CDDP and 50 μM SFU was statistically analysed. H, I, J Real-time RT-PCR analysis showed deregulated mtDNA-encoded subunit genes in 5FU-resistant (5FU-R) SAS cells and CDDP-resistant (CDDP-R) OE CM1 and HSC3 cells compared with their sensitive counterparts (SFU-S and CDDP-S), respectively. Data are presented as Mean±SEM (N = 3 independent biological replicates). For 2 C–2 F, each dot in bar graph represents an individual biological replicate. VA Vector alone, hTFAM Full-length wild-type human TFAM. *p < 0.05, **p < 0.01, ***p < 0.001.

Cell Death and Disease (2021) 12:961
were downregulated in response to TFAM reduction in HNC cells compared with control cells (Fig. 5C). Interestingly, HNC patients with TFAM genetic mutation (K141N) exhibited worse Overall Survival (OS) rate than HNC patients without TFAM alteration (Median Survival: 22.19 months vs. 56.94 months) indicating that maintenance of TFAM integrity might be important for HNC development (Fig. 6E, F). Further analysis to clarify whether mtDNA drop could also be evident during HNC progression in vivo and in clinic, 13 mtDNA encoded ETC genes from 8-, 12- and 16-week control and Nqo-induced mouse tongue tissues was examined. By RNA-seq analysis, it was found that mtDNA encoded ETC subunits were transcriptionally down-regulated in Nqo groups compared to control group and, between Nqo treated groups, mtDNA encoded ETC genes were dropped with prolonged Nqo treatment, suggesting that decrease of mtDNA encoded ETC subunits could be a predisposition factor for mouse tongue cancer development (Fig. 6C, D).

The expression of TFAM and its downstream targets was further examined in paired adjacent normal (N) and tumour (T) clinical tissues from HNC patients (N = 18; Table S1). In agreement with database analysis, TFAM mRNA expression of all mtDNA encoded ETC genes were significantly downregulated in tumours compared with corresponding normal tissues, suggesting that decreased TFAM levels might be important for HNC development (Fig. 6E, F). Further analysis to define a potential association of TFAM/mtDNA encoded ETC gene expression and disease progression stratified by TNM scaling was next determined. Even though the data showed no statistical significance, all mtDNA encoded ETC genes showed a decreasing trend over a T score (from T1 to T4) and N stages (from N0 to N2) (Fig. S11–12), suggesting that mtDNA encoded ETC genes reversely associated with disease severity. To draw a more definite conclusion, a larger number HNC samples would be required.

DISCUSSION

In the present study, we discovered that lower TFAM and mtDNA expression led to decreased mitochondrial activity, which elicited oncogenic pathways to promote tumour

---

**Fig. 3** TFAM silencing elicits metabolic reprogramming in HNC cells. No significant changes of (A) Glucose uptake, (B) Intracellular pyruvate and (C) ATP levels were found in TFAM-silenced HNC cells compared with control cells. In contrast, hTFAM overexpression dominantly modulated these metabolic indices in both shLuc and shTFAM transfected HNC cells compared with control (VA) transfectants. D Significant increasing extracellular lactate levels and (E) decreasing Pyruvate Dehydrogenase activity were detected in most TFAM -silenced HNC cells. Introduction of hTFAM largely reversed these metabolic states in both shLuc and shTFAM transfected HNC cells compared with VA transfectants. Data are presented as Mean ± SEM. Each dot (N ≥ 3) in bar graph represents an individual biological replicate. VA Vector alone, hTFAM Full-length wild-type human TFAM. *p < 0.05, **p < 0.01, ***p < 0.001.
proliferation, mobility and therapeutic sensitivity. At molecular basis, we further demonstrated that ERK1/2 and Akt-mTORC-S6 pathways were highly active in TFAM-silenced HNC cells and treatment of ERK/Akt inhibitors effectively repealed TFAM-mediated malignant changes. In contrast, enforced TFAM expression suppressed cancerous identity and reversed Warburg phenotype, indicating that TFAM actively contribute to modulation of HNC malignant features. In agreement with in vitro and in vivo findings, it was also found that TFAM and mtDNA encoded ETC genes were downregulated in Nqo treated mouse tongue cancer and clinic HNC tissues compared with their normal counterparts. In summary, our findings provide strong evidence showing that [1] TFAM is critical for mtDNA replication/transcription in HNCs [2]; TFAM loss/overexpression is sufficient to modulate HNC malignancy via metabolic reprogramming towards a cancer favourable metabolic state and modulations of oncogenic effector Akt and ERK pathways; and [3] expression of TFAM and mtDNA encoded ETC genes could predict HNC progression in preclinical and clinical specimens prior to conventional treatments.

Based on previous investigations, TFAM does not always act as a suppressor in cancers, as summarized in Table S5, while TFAM is enriched and could promote cancer cell proliferation and metastasis in bladder [45], oesophageal [46], gastric [47] and colon cancers [48]. It is suspected that the discrepant roles of TFAM in different cancers could possibly be attributed to distinct metabolic features in order to adapt to different tumour microenvironments [49]. Moreover, as genetic
mutations/polymorphisms of mtDNA genes might also be a key factor in controlling tumour cell malignancy [50, 51]; a detection of mutations in mt-ND2, mt-ND4, mt-ATP8 and mt-CytB in tested HNC cell lines (Table S6) highlighted great necessity to further define the impacts of these mtDNA mutations during HNC development, in an attempt to find a diagnostic marker for HNCs.

Another interesting discovery from our results are [1]: TFAM seems impacted differentially for extrinsic and intrinsic metabolic cues since no significant changes for glucose uptake, intracellular ATP level and pyruvate content were detected whereas elevated aerobic glycolysis was evident in TFAM-silenced HNC cells. Results from these metabolic assays suggested that TFAM loss does alter HNC cell metabolism; however, the reprogramming seems to be the outcome of rewiring of intracellular metabolites but not external nutrient inputs and [2] Unlike the dogmatic role of ROS to trigger cell death, current findings surprisingly demonstrated that ROS level is elevated in mitochondrial defective TFAM-silenced HNC cells and increased ROS level likely plays a critical role in regulating tumour growth through the activation of pro-tumourgenic cues. In agreement with our data, numerous studies have also found that ROS could induce PI3K/Akt/mTORs activity in various cancers [52, 53], suggesting that excessive ROS may serve as a promoter for neoplastic transformation. Taken together, TFAM expression is critical to control metabolic mediated regulations in HNCs.

It is widely accepted that cancers are metabolically dynamic in order to survive in different environmental challenges. It therefore becomes convincing that targeting tumour metabolic plasticity could be capable of improving therapeutic efficacy of anti-cancer schemes [53]. In agreement with this concept, we found that suppression of TFAM-silenced induced ERK1/2 and Akt activity by commercial inhibitors could...
effectively abolish cell viability in highly-proliferating TFAM-silenced HNC cells, implying that targeting intracellular molecular changes, in combination with metabolic manipulation, could likely develop a more efficient treatment regimen in the clinic. In addition to intracellular molecular changes, mitochondrial manipulation could also result in mitochondria-independent metabolic alterations in different cancers. By taking advantage of transcriptomics technology, a previous study found that TFAM loss led to increased angiogenesis and invasion as well as genes relates to amino acid metabolism [e.g., SLC1A5 (ASCT2) and SLC1A4 (ASCT1)] in melanoma cells [49], suggesting that, in order to gain better anti-cancer therapeutic efficacy, it is important to define molecular and metabolic features upon mitochondrial manipulations in order to target the correct cue(s) for combinational therapy.

In conclusion, we highlighted the prominent role of TFAM in regulating HNC malignancy and confirmed that TFAM could be a key tumour suppressor during HNC tumourigenesis (Fig. 7). We hope our findings could potentially shed the light on the development of new TFAM/mtDNA based diagnostic scheme to early detection of HNCs.
Fig. 7 Decreasing TFAM/mitDNA contributes HNC pathogenesis. mtDNA encoded gene expression declines during HNC initiation. Further loss of TFAM/mitDNA triggers HNC malignant progression via multifaceted metabolic and molecular alterations.

DATA AVAILABILITY
The data presented in the current study are available upon reasonable request from the corresponding author.

REFERENCES
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
2. Warburg O. On the origin of cancer cells. Science 1956;123:309–14.
3. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.
4. Cannino G, Ciscato F, Masgras I, Sanchez-Martin C, Rasola A. Metabolic plasticity of tumor cell mitochondria. Front Oncol. 2018;8:333.
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–33.
6. Torresano L, Nuevo-Tapioles C, Santacatterina F, Cuezva JM. Metabolic reprogramming and disease progression in cancer patients. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165721.
7. Li WC, Huang CH, Hsieh YT, Chen TY, Cheng LH, Chen CY, et al. Regulatory role of hexokinase 2 in modulating head and neck tumorigenesis. Front Oncol. 2020;10:176.
8. Hsieh YT, Chen YF, Lin SC, Chang KW, Li WC. Targeting cellular metabolism modulates head and neck oncogenesis. Int J Mol Sci 2019;20:16.
9. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metastasis. Cancer Lett. 2015;356:197–203.
10. Kang JH, Lee SH, Hong D, Lee JS, Ahn HS, Ahn JH, et al. Aldehyde dehydrogenase is used by cancer cells for energy metabolism. Exp Mol Med. 2016;48:e272.
11. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer. Cancer Disc. 2015;5:1024–39.
12. Bajpai R, Sharma A, Achreja A, Edgar CL, Wei C, Siddiqua AA, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020;11:1228.
13. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest. 2013;123:3652–8.
14. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011;1807:1432–43.
15. Friedman JR, Nunnari J. Mitochondrial form and function. Nature 2014;505:335–43.
16. Femire AR, Carrari F, Sweetlove LJ. Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol. 2004;7:254–61.
17. Gaspari M, Larsson NG, Gustafsson CM. The transcription machinery in mammalian mitochondria. Biochim Biophys Acta. 2004;1659:148–52.
18. Torralba D, Baixauli F, Sanchez-Madrid F. Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer. Front Cell Dev Biol. 2016;4:107.
19. Kleih M, Boppel K, Dong M, Gaissler A, Heine S, Olayioye MA, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10:851.
20. Masuzaki Y, Tanaka K, Makino T, Yamasaki M, Miyazaki Y, Takahashi T, et al. Eosphagial squamous cell carcinoma with low mitochondrial DNA content shows mesenchymal and stem-like characteristics, and contributes to poor prognosis. PLoS One. 2018;13:e0193159.
21. Cui H, Huang P, Wang Z, Zhang Y, Zhang Z, Xu W, et al. Association of decreased mitochondrial DNA content with the progression of colorectal cancer. BMC Cancer. 2013;13:110.
22. Takeda D, Hasegawa T, Ueha T, Sakakibara A, Kawamoto T, Minamikawa T, et al. Decreased mitochondrial copy numbers in oral squamous cell carcinoma. Head Neck. 2016;38:1170–5.
23. Ballett RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle. 2011;10:4065–73.
24. Woo DK, Green PD, Santos JH, D’Souza AD, Walther Z, Martin WD, et al. Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC (Min/−) mice. Am J Pathol 2012;180:24–31.
25. Jiang X, Wang J. Knockdown of TFAM in Tumors Retarded Autophagic Flux through Regulating p53 Acetylation and P30 Expression. Cancers (Basel). 2020;12:493.
26. Chen TY, Hsieh YT, Huang JM, Liu CJ, Chung LT, Huang PC, et al. Determination of pyruvate metabolic fate modulates head and neck tumorigenesis. Neoplasia 2019;21:641–52.
27. Chen YC, Hunter DJ. Molecular epidemiology of cancer. CA Cancer J Clin 2005;55:45–54; quiz 7.
28. Chen YC, Hunter DJ. Molecular epidemiology of cancer. CA Cancer J Clin 2005;55:45–54; quiz 7.
29. Liu CJ, Chang WJ, Chen CY, Sun FJ, Cheng HW, Chen TY, et al. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis. Oncotarget 2015;6:29268–84.
30. Kim HAJ, Zeng PYY, Shaikh MH, Mundi N, Ghosemi F, Di Gravio E, et al. All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles. Oral Oncol. 2021;116:105260.
31. Paul CD, Mistrutti P, Konstantopoulos K. Cancer cell motility: lessons from migration in confined spaces. Nat Rev Cancer. 2017;17:131–40.
32. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769–92.
33. Mizutani S, Miyato Y, Shidara Y, Asoh S, Tokunaga A, Tajiri T, et al. Mutations in mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci. 2009;100:1680–7.
34. Aminuddin A, Ng PY, Leong CO, Chua EW. Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma. Sci Rep. 2020;10:7885.
35. Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stefanopoulos G. Metabolic requirements for cancer cell proliferation. Cancer Metab. 2016;4:16.
36. Malhotra J. Molecular and genetic epidemiology of cancer in low- and medium-income countries. Ann Glob Health. 2014;80:148–25.
37. Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, et al. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene 2018;37:377–88.
ACKNOWLEDGEMENTS

Authors would like to thank Professor Kuo-Wei Chang (National Yang-Ming University) for providing experimental materials. We thank the National RNAi Core Facility at Academia Sinica, Taiwan for providing shRNA reagents. We also thank Dr Jude Clapper (Taipei American School) for critical review and English corrections for the manuscript. This work is supported by grants MOST-106-2314-B-010-005-MY3, Most-109-2628-B-010-008-, Most-110-2628-B-49A-511- and Most-110-2314-B-49A-516-MY3 from Ministry of Science and Technology, Taiwan.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The present study was approved by the Institutional Review Boards (IRB) of NYMU Hospital (IRB#: NYMUH 2018B003). Animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC), National Yang-Ming University (NYMU).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04255-w.

Correspondence and requests for materials should be addressed to Wan-Chun Li.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021